Eiseman JL - Search Results

1

Glyoxalase I inhibitors in cancer chemotherapy.

Creighton DJ, Zheng ZB, Holewinski R, Hamilton DS, Eiseman JL. Creighton DJ, et al. Among authors: eiseman jl. Biochem Soc Trans. 2003 Dec;31(Pt 6):1378-82. doi: 10.1042/bst0311378. Biochem Soc Trans. 2003. PMID: 14641067 Review.

2

N-(2-hydroxypropyl)methacrylamide copolymers of a glutathione (GSH)-activated glyoxalase i inhibitor and DNA alkylating agent: synthesis, reaction kinetics with GSH, and in vitro antitumor activities.

Zheng ZB, Zhu G, Tak H, Joseph E, Eiseman JL, Creighton DJ. Zheng ZB, et al. Among authors: eiseman jl. Bioconjug Chem. 2005 May-Jun;16(3):598-607. doi: 10.1021/bc0499634. Bioconjug Chem. 2005. PMID: 15898727

3

Mechanism-based competitive inhibitors of glyoxalase I: intracellular delivery, in vitro antitumor activities, and stabilities in human serum and mouse serum.

Kavarana MJ, Kovaleva EG, Creighton DJ, Wollman MB, Eiseman JL. Kavarana MJ, et al. Among authors: eiseman jl. J Med Chem. 1999 Jan 28;42(2):221-8. doi: 10.1021/jm9708036. J Med Chem. 1999. PMID: 9925727

4

A new method for rapidly generating inhibitors of glyoxalase I inside tumor cells using S-(N-aryl-N-hydroxycarbamoyl)ethylsulfoxides.

Hamilton DS, Kavarana MJ, Sharkey EM, Eiseman JL, Creighton DJ. Hamilton DS, et al. Among authors: eiseman jl. J Med Chem. 1999 May 20;42(10):1823-7. doi: 10.1021/jm980712o. J Med Chem. 1999. PMID: 10346934

5

Pharmacokinetics and antitumor properties in tumor-bearing mice of an enediol analogue inhibitor of glyoxalase I.

Sharkey EM, O'Neill HB, Kavarana MJ, Wang H, Creighton DJ, Sentz DL, Eiseman JL. Sharkey EM, et al. Among authors: eiseman jl. Cancer Chemother Pharmacol. 2000;46(2):156-66. doi: 10.1007/s002800000130. Cancer Chemother Pharmacol. 2000. PMID: 10972486

6

Selective inhibition of MCF-7(piGST) breast tumors using glutathione transferase-derived 2-methylene-cycloalkenones.

Joseph E, Ganem B, Eiseman JL, Creighton DJ. Joseph E, et al. Among authors: eiseman jl. J Med Chem. 2005 Oct 20;48(21):6549-52. doi: 10.1021/jm058245f. J Med Chem. 2005. PMID: 16220971

7

Molecular basis of the antitumor activities of 2-crotonyloxymethyl-2-cycloalkenones.

Joseph E, Eiseman JL, Hamilton DS, Wang H, Tak H, Ding Z, Ganem B, Creighton DJ. Joseph E, et al. Among authors: eiseman jl. J Med Chem. 2003 Jan 2;46(1):194-6. doi: 10.1021/jm0203027. J Med Chem. 2003. PMID: 12502374

8

Plasma pharmacokinetics and tissue distribution of the breast cancer resistance protein (BCRP/ABCG2) inhibitor fumitremorgin C in SCID mice bearing T8 tumors.

Garimella TS, Ross DD, Eiseman JL, Mondick JT, Joseph E, Nakanishi T, Bates SE, Bauer KS. Garimella TS, et al. Among authors: eiseman jl. Cancer Chemother Pharmacol. 2005 Feb;55(2):101-9. doi: 10.1007/s00280-004-0866-2. Epub 2004 Oct 1. Cancer Chemother Pharmacol. 2005. PMID: 15580504

9

Tumor-targeted apoptosis by a novel spermine analogue, 1,12-diaziridinyl-4,9-diazadodecane, results in therapeutic efficacy and enhanced radiosensitivity of human prostate cancer.

Eiseman JL, Rogers FA, Guo Y, Kauffman J, Sentz DL, Klinger MF, Callery PS, Kyprianou N. Eiseman JL, et al. Cancer Res. 1998 Nov 1;58(21):4864-70. Cancer Res. 1998. PMID: 9809992

10

Inositol hexaphosphate (IP6) enhances the anti-proliferative effects of adriamycin and tamoxifen in breast cancer.

Tantivejkul K, Vucenik I, Eiseman J, Shamsuddin AM. Tantivejkul K, et al. Breast Cancer Res Treat. 2003 Jun;79(3):301-12. doi: 10.1023/a:1024078415339. Breast Cancer Res Treat. 2003. PMID: 12846414

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

113 results

Search Page

Filters